Potential Indications of Dupilumab in Th-2 Inflammatory Disease
Rev Recent Clin Trials. 2023 Dec 20. doi: 10.2174/0115748871263396231121060901. Online ahead of print.ABSTRACTDupilumab is a fully humanized IgG4 monoclonal antibody, inhibiting IL-4 and IL-13 signaling, which are the main cytokines involved in type 2 inflammatory diseases. Its introduction was a breakthrough in the treatment of moderate-to-severe atopic dermatitis, but it is also used in other inflammatory diseases, including asthma, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis. Recent advances in the understanding of inflammatory pathways have revealed that Th2-type inflammation is involved in...
Source: Reviews on Recent Clinical Trials - December 23, 2023 Category: Cancer & Oncology Authors: Proietti Ilaria Skroza Nevena Tolino Ersilia Bernardini Nicoletta Federica Trovato Marco Di Fraia Dybala Agniezska Potenza Concetta Source Type: research
Potential Indications of Dupilumab in Th-2 Inflammatory Disease
Rev Recent Clin Trials. 2023 Dec 20. doi: 10.2174/0115748871263396231121060901. Online ahead of print.ABSTRACTDupilumab is a fully humanized IgG4 monoclonal antibody, inhibiting IL-4 and IL-13 signaling, which are the main cytokines involved in type 2 inflammatory diseases. Its introduction was a breakthrough in the treatment of moderate-to-severe atopic dermatitis, but it is also used in other inflammatory diseases, including asthma, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis. Recent advances in the understanding of inflammatory pathways have revealed that Th2-type inflammation is involved in...
Source: Reviews on Recent Clinical Trials - December 23, 2023 Category: Cancer & Oncology Authors: Proietti Ilaria Skroza Nevena Tolino Ersilia Bernardini Nicoletta Federica Trovato Marco Di Fraia Dybala Agniezska Potenza Concetta Source Type: research
Potential Indications of Dupilumab in Th-2 Inflammatory Disease
Rev Recent Clin Trials. 2023 Dec 20. doi: 10.2174/0115748871263396231121060901. Online ahead of print.ABSTRACTDupilumab is a fully humanized IgG4 monoclonal antibody, inhibiting IL-4 and IL-13 signaling, which are the main cytokines involved in type 2 inflammatory diseases. Its introduction was a breakthrough in the treatment of moderate-to-severe atopic dermatitis, but it is also used in other inflammatory diseases, including asthma, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis. Recent advances in the understanding of inflammatory pathways have revealed that Th2-type inflammation is involved in...
Source: Reviews on Recent Clinical Trials - December 23, 2023 Category: Cancer & Oncology Authors: Proietti Ilaria Skroza Nevena Tolino Ersilia Bernardini Nicoletta Federica Trovato Marco Di Fraia Dybala Agniezska Potenza Concetta Source Type: research
Clinical and immunopathological characteristics of autoimmune blistering skin diseases
Acta Dermatovenerol Alp Pannonica Adriat. 2023 Dec;32(4):141-149.ABSTRACTAutoimmune blistering skin diseases (AIBDs) encompass several heterogeneous conditions clinically characterized by blisters and erosions on the skin and mucous membranes and are immunopathologically characterized by autoantibodies against structural proteins of the skin. Those proteins are responsible for the intercellular contact between epidermal keratinocytes and adhesion of the basal keratinocytes to the dermis. Therefore, AIBDs are divided into two main groups: intraepidermal (the pemphigus group) and subepidermal (the pemphigoid) groups. The dia...
Source: Acta Dermatovenerologica Alpina, Panonica, et Adriatica - December 21, 2023 Category: Dermatology Authors: Anita Gunari ć Dubravka Šimić Branka Marinovi ć Source Type: research
